Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

0 Calificaciones
0
Episodio
215 of 219
Duración
30min
Idioma
Inglés
Formato
Categoría
Economía y negocios

Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy —as one of the only women of color leading a major pharmaceutical company.

This episode was recorded on April 23, 2025. Learn more about your ad choices. Visit megaphone.fm/adchoices


Escucha y lee

Descubre un mundo infinito de historias

  • Lee y escucha todo lo que quieras
  • Más de 900,000 títulos
  • Títulos exclusivos + Storytel Originals
  • 7 días de prueba gratis, luego $169 MXN al mes
  • Cancela cuando quieras
Suscríbete ahora
Copy of Device Banner Block 894x1036 3
Cover for Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech

Otros podcasts que te pueden gustar...